NextCure Inc (NXTC) FinancialsNXTCNextCure Inc

Evaluating the bottom line, NextCure Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.22%, provide a clear picture of how effectively NXTC converts its operational activities into shareholder value.

In the context of the broader market, NXTC competes directly with industry leaders such as MGX and AARD. With a market capitalization of $24.27M, it holds a significant position in the sector. When comparing efficiency, NXTC's gross margin of N/A stands against MGX's 100.00% and AARD's N/A. Such benchmarking helps identify whether NextCure Inc is trading at a premium or discount relative to its financial performance.

NextCure's financials show significant net losses, with a net income of -26808000 in Q2 2025 and a gross profit of -633000 in the same quarter. The current ratio remains strong at 3.47, indicating good short-term liquidity, but the overall financial performance is concerning due to ongoing losses.